Preclinical Metabolite Identification & Toxicity Screening Services
At Ace Therapeutics, we recognize that understanding a drug candidate's metabolic fate and toxicity profile is critical to overcoming the high attrition rates in Alzheimer's disease (AD) research. Our specialized preclinical services focus on identifying neurotoxic metabolites, evaluating species-specific risks, and ensuring your candidates meet stringent safety benchmarks—long before they advance further in development.
Alzheimer's therapeutics face unique challenges, from blood-brain barrier (BBB) penetration to mitigating off-target effects in aging brains. Unstable metabolites or undetected neurotoxicity can derail years of research. Our tailored workflows address these risks by
Identify and characterize metabolites with precision using advanced platforms.
Evaluate risks specific to Alzheimer's pathophysiology.
Ensure your candidates meet global safety standards.
Explore how gut microbiome-derived metabolites influence AD progression.
To address the multifaceted nature of Alzheimer's R&D, we deploy innovative platforms.
| Technology | Application |
| AI-driven toxicity prediction | Prioritizes compounds with low neurotoxicity risks using QSAR models. |
| 3D BBB-organoid chips | Mimics human blood-brain barrier for metabolite transport studies. |
| High-resolution mass spec | Detects trace-level genotoxic impurities in complex matrices. |
| Microsomal stability testing | Evaluates metabolic stability of acetylcholinesterase inhibitors. |
In the high-stakes field of Alzheimer's research, early metabolite and toxicity insights can mean the difference between success and failure. Let Ace Therapeutics equip you with the data and confidence to propel your candidates forward. Contact us today to design a tailored preclinical strategy.
How do you handle species-specific differences in metabolite toxicity
We perform parallel studies in human hepatocytes and rodent models, followed by cross-species comparative analysis to flag translational risks.
Can you screen for gut microbiome-linked neurotoxins
Yes. Our co-culture systems integrate intestinal epithelial cells with neuronal models to study microbiome-metabolite interactions.
What sample quantities are required for metabolite profiling
Most assays require <1 mg of compound. Microsampling techniques further reduce material needs for scarce candidates.
Do you support biologics or gene therapies for AD
Absolutely. We've optimized LC-MS/MS and ELISA protocols for large molecules, including antibodies targeting Aβ and tau.
How long does a typical neurotoxicity screening package take
Turnaround times range from 4 weeks (high-throughput ROS assays) to 12 weeks (comprehensive 3D organoid studies).
Our products and services are for research use only and can not be used for diagnostic or other purposes.
Make Order
Experimental Scheme
Implementation
Conclusion
Ace Therapeutics is a specialized team of scientists and technical professionals committed to working closely with clients worldwide. We offer comprehensive preclinical testing solutions to support the development of novel therapies and medications across a range of disease areas.
Ace Therapeutics boasts a team of highly committed and skilled researchers dedicated to delivering innovative preclinical contract research solutions.
We provide tailored preclinical services designed to streamline your research process and advance promising concepts into actionable insights, ensuring efficient progress in drug development.